clinical trial · NCT06805864
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
Gunma University·phase2·not yet recruiting·n = 45
Cervical AdenocarcinomaCervical Adenosquamous CarcinomaPembrolizumab (KEYTRUDA®)
brief summary
The goal of this clinical trial is to learn if pembrolizumab works for cervical adenocarcinoma treat with concurrent chemo-carbon-ion radiaotherapy (CIRT). The main questions it aims to answer are: • Does concurrent chemo-CIRT with pembrolizumab improves 2-year progression-free survival (PFS), compared with concurrent chemoradiotherapy with conventional X-rays?
started
Feb 1, 2025
primary completion
Dec 31, 2029
completion
Dec 31, 2030
last updated
Feb 3, 2025
official title
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma (BROTHER STUDY)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol